Conclusions & Recommendations

Outline on the maps the districts being requested so that they're easier to find

Use bigger font on supply chain slides and break out modified strategies as a separate color on the graphs so the additional drug for modified strategies can be visualized

Include national program manager participation at future TEC meetings when applications being presented are non-routine and to hear feedback on their implementation of modified strategies

Draft a manuscript for publication on the challenges facing national programs, authored by the 6 countries that presented applications at TEC 26

TEC 28: November 15 – 17, 2022 in Cape Town, South Africa – suggested agenda items include:
- Reviewing data from co-administration trials
- Updates from REACH trials (particularly Côte d’Ivoire, ideally including participation by the national program coordinator)
- A focus on Antimicrobial Resistance (AMR) monitoring and how it may affect communication between TEC members and partners

TEC 27: June 13 – 16, 2022 in Atlanta, GA, USA – an extra day has been added to allow more discussion time for Category 1 & 2 district decision-making.

TEC 26: March 29-31, 2022 in London, UK – This meeting will focus on reconsidering TEC decisions for 2022 in Category 1 & 2 districts. Participants will include TEC, implementing partners and donors and program managers in countries with 2022 Applications in Category 1 & 2 districts that would like to propose a different strategy

TEC recommends that ITI Management track Category 1 & 2 requests, TEC allocation decisions in those districts, and lessons learned as this new TEC guidance is implemented

TEC recommends that ITI and the TEC liaisons work closely with national programs, their implementing partners, and donors in each country with Category 1 & 2 districts to:
- help interpret the new guidance, and
-develop a package of information supporting TEC’s consideration of Applications at TEC 26 (2022 treatments) & TEC 27 (2023 treatments)

ITI to draft a letter for TEC review to communicate changes to the national programs and partners about Zithromax® decision-making in Category 1 & 2 districts based on recommendations from the WHO Informal Consultation, AND information about catch-up rounds in other districts.